Sierra Neuropharma Raises $21.5M in Series A

Sierra Neuropharmaceuticals Inc., a developer of direct-to-brain treatment methods and medications, announced Thursday that it has concluded its initial round of venture financing after raising some $21.5 million. Sierra credited HealthCare Ventures, Morgenthaler Ventures and Sequel Venture Partners with leading the effort. High Country Venture and GC&H Investments LLC also participated, Sierra said. Headquartered in the Denver suburb of Aurora, Colo., Sierra Neuropharmaceuticals formulates drugs for the treatment of severe central nervous system diseases. Sierra is currently focused on using implantable pumps that are surgically placed beneath the skin and delivered directly to the fluid surrounding the brain via a catheter. More information »